Neuropace
NPCE
28 hedge funds and large institutions have $53.1M invested in Neuropace in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 7 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.79% less ownership
Funds ownership: 74.88% → 73.08% (-1.8%)
13% less funds holding
Funds holding: 32 → 28 (-4)
26% less capital invested
Capital invested by funds: $71.4M → $53.1M (-$18.3M)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$667K |
| 2 |
Millennium Management
New York
|
+$378K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$149K |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$126K |
| 5 |
FAIM
Financial Advocates Investment Management
Olympia,
Washington
|
+$48.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Revelation Capital Management
Sausalito,
California
|
-$989K |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$855K |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$576K |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$168K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$108K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BWM
26
BerganKDV Wealth Management
Bloomington,
Minnesota
| $2K | – | – | – |
|
27
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$390 | +81 | +55% |
|
|
28
Citadel Advisors
Miami,
Florida
| – | -$108K | -21,692 | Closed |
|
29
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$15K | -3,000 | Closed |
|
|
CSS
30
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$3K | -651 | Closed |
|
31
Wells Fargo
San Francisco,
California
| – | +$207 | +43 | +100% |
|
NPCE Hedge Fund Activity: Q3 2022 in Review
28 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q3 2022, worth a combined $53.1M — down 26% from $71.4M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of NPCE and 3 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 10 added.
The largest buyer was Morgan Stanley, adding an estimated $667K. The largest seller was Revelation Capital Management, cutting an estimated $989K.
- 28 institutional investors held Neuropace (NPCE) as of Q3 2022, down from 32 in Q2 2022.
- Funds reported $53.1M of Neuropace stock for Q3 2022, down 26% quarter-over-quarter.
- 3 funds opened new Neuropace positions in Q3 2022 and 7 closed out, a net change of -4 holders.
- The largest Neuropace buyer in Q3 2022 was Morgan Stanley, an estimated $667K added.
- The largest Neuropace seller in Q3 2022 was Revelation Capital Management, an estimated $989K sold.
Based on aggregated 13F filings for Q3 2022.